daunorubicin has been researched along with deoxycytidine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuddy, DP; de Valeriola, DL; Egorin, MJ; Forrest, A; Ross, DD | 1 |
| Alvord, WG; Gazdar, AF; Gray-Goodrich, M; Koo, HM; McWilliams, MJ; Mikheev, A; Monks, A; Oie, HK; Paull, KD; Rubinstein, LV; Vande Woude, GF; Zarbl, H | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; Veerman, G | 1 |
| Bergman, AM; Jensen, PB; Munch-Petersen, B; Peters, GJ; Pinedo, HM; Sehested, M; Smid, K; Veerman, G; Voorn, DA | 1 |
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
6 other study(ies) available for daunorubicin and deoxycytidine
| Article | Year |
|---|---|
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Deoxycytidine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Tumor Cells, Cultured | 1991 |
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Cytarabine; Daunorubicin; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Software; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Daunorubicin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Gemcitabine; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1998 |
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Carcinoma, Small Cell; Cell Survival; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Guanosine Triphosphate; Humans; Lung Neoplasms; Nucleoside Deaminases; Teniposide; Thymidine Kinase; Tumor Cells, Cultured; Uridine Triphosphate | 2001 |
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |